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Abstract
Background:  The mesolimbic structures of the brain are important in the anticipation and
perception of reward. Moreover, many drugs of addiction elicit their response in these structures.
The M5 muscarinic receptor (M5R) is expressed in dopamine-containing neurones of the substantia
nigra pars compacta and ventral tegmental area, and regulates the release of mesolimbic dopamine.
Mice lacking M5R show a substantial reduction in both reward and withdrawal responses to
morphine and cocaine. The CHRM5, the gene that codes for the M5R, is a strong biological
candidate for a role in human addiction. We screened the coding and core promoter sequences of
CHRM5 using denaturing high performance liquid chromatography to identify common
polymorphisms. Additional polymorphisms within the coding and core promoter regions that were
identified through dbSNP were validated in the test population. We investigated whether these
polymorphisms influence substance dependence and dose in a cohort of 1947 young Australians.  
Results: Analysis was performed on 815 participants of European ancestry who were interviewed
at wave 8 of the cohort study and provided DNA. We observed a 26.8% increase in cigarette
consumption in carriers of the rs7162140 T-allele, equating to 20.1 cigarettes per week (p=0.01).
Carriers of the rs7162140 T-allele were also found to have nearly a 3-fold increased risk of
developing cannabis dependence (OR=2.9 (95%CI 1.1-7.4); p=0.03).  
Conclusion: Our data suggest that variation within the CHRM5 locus may play an important role
in tobacco and cannabis but not alcohol addiction in European ancestry populations. This is the first
study to show an association between CHRM5 and substance use in humans. These data support
the further investigation of this gene as a risk factor in substance use and dependence.
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Background
The muscarinic acetylcholine M5 receptor (M5R) is a
member of the family of G-protein coupled receptors. The
M5R is the only muscarinic receptor subtype expressed in
the ventral tegmetal area (VTA) and substantia nigra pars
compacta (SNc) [1-3], where it is co-localised with
dopamine D2 receptors on dopaminergic neurones [1].
There is considerable evidence to suggest that stimulation
of dopaminergic pathways within the VTA and SNc gives
rise to the subjective experience of pleasure and reward.
Drugs of addiction, such as tobacco, alcohol, cannabis,
cocaine and opiates, are thought to exert their reinforcing
effects by elevating dopamine levels within the mesolim-
bic structures [4]. While the exact biological mechanisms
that determine substance-driven reward are poorly under-
stood, genes involved in the regulation of dopaminergic
neurotransmission are thought to be key components in
this process. The M5R is believed to modulate dopamin-
ergic neurotransmission within VTA and SNc dopamine
neurones [5]. Specifically, the M5R is thought to control
the duration of dopamine release [1,6,7].
Animal models show that the M5R plays an important
role in modulating substance addiction. Mice lacking a
functional M5R were shown to have reduced reward and
withdrawal responses following morphine [8] and
cocaine [9] administration. Tobacco, alcohol and canna-
bis exert their reinforcing effects through similar
dopaminergic mechanisms to cocaine and opiates [4].
Consequently, the gene coding for the human M5R,
CHRM5 (GeneID: 1133) is a strong biological candidate
for studies looking at genetic influence on addiction to
tobacco, alcohol and cannabis.
The purpose of this study was two-fold. Firstly, to screen
the complete coding, untranslated and putative "core"
promoter regions of CHRM5 for common polymorphic
variation. Secondly, to assess the association between
identified polymorphic loci and drug dependence in a
large cohort of young adults. To our knowledge this is the
first study to report a systematic screening for polymor-
phisms within the CHRM5  locus. Consequently, there
have been no association studies investigating the contri-
bution of natural genetic variation at this locus to risk of
substance dependence.
Results
Analysis of the CHRM5 locus
CHRM5  (LocusID: 1133), the gene that codes for the
M5R, is located at 15q26. In silico analysis of the CHRM5
locus identified two mRNA species, CHRM5. a (described
by accession number: AB084282,) and CHRM5. b
(described by accession number: AK095198). The gene is
alternatively spliced with two transcripts CHRM5. a and
CHRM5. b containing a common 3'-coding exon and
three alternatively spliced 5'-untranslated exons (see Fig-
ure 1). Both species contain the coding exon 4 with alter-
native splicing in the 5'untranslated region. Alignment of
CHRM5. a onto chromosome 15 reference sequence
reveals a gene of two exons; a 5'-untranslated exon of 244
bp (exon 2), separated by an intron of 44.2 kbp from a 2.4
kbp exon (exon 4) containing the entire coding sequence.
The CHRM5. b comprises of two 5'-untranslated exons of
263 bp (exon 1) and 332 bp (exon 3) respectively sepa-
rated from each other and exon 4 by intronic regions of
77.4 kbp and 15.8 kbp respectively. An illustration of this
gene structure is shown in Figure 1.
Identification of polymorphic variation in the CHRM5 
locus
Using denaturing high-performance liquid chromatogra-
phy (DHPLC), we screened 4588 bp of genomic sequence
of CHRM5, including all of the sequence represented in
the final mRNA and both core promoter regions for the
transcripts CHRM5. a and CHRM5. b. The chosen screen-
ing regions are highlighted on Figure 1. We identified
three polymorphisms by this method, rs661968,
rs7162140 and CHRM5b*-257A>T. We determined allele
frequencies of the polymorphic SNPs in a subset of our
test population; minor allele frequencies were 3.2%
(rs661986), 19.0% (rs7162140) and 2.8% (CHRM5b. -
257A>T). In the course of this study rs661968 and
rs7162140 were described in the public sequence varia-
tion (dbSNP) database. Analysis of our screening region
within the dbSNP database identified four polymor-
phisms not detected by DHPLC in our screening region
(rs2702309, rs2702304, rs2576302 and rs2705353).
None of the four variants identified were polymorphic in
our test population.
Association of rs7162140 and substance dependence
Of the seven polymorphisms identified within our screen-
ing region only rs7162140 was of sufficient frequency for
association analysis. We examined nicotine dependence,
tobacco dose, alcohol dependence, alcohol dose and can-
nabis dependence. A summary of genotype association
data for dependence measures are shown in Table 1.
Tobacco use
For tobacco use behaviours, we found no evidence of sus-
ceptibility to nicotine dependence with respect to the
rs7162140 T-allele under either the dominant or recessive
model. Interstingly, we observed a substantial increase in
tobacco dose (dominant model) among carriers of the T-
allele. Carriers of the T-allele smoked on average 20.1 cig-
arettes more per week than individuals who were
homozygous for the C-allele (CC = 74.9 cpw (SEM 4.0),
CT|TT = 95.0cpw (SEM 7.6)), (nominal p = 0.01) (see
Table 2).BMC Genetics 2007, 8:46 http://www.biomedcentral.com/1471-2156/8/46
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Alcohol use
We did not find any evidence to support a role of
rs7162140 and alcohol dose or dependence (see Table 1
and Table 2).
Cannabis use
Genotype analysis revealed a nearly three-fold increased
risk observed under a T-allele dominant model (Odds
ratio = 2.9 (95%CI 1.1–7.4), nominal p = 0.03) (see Table
1).
Discussion
This study reports a systematic screen of the known tran-
scribed and core promoter regions of the human CHRM5.
We identified seven variants within the screening regions,
three by DHPLC and four additional variants through
public sequence variation repositories. Only polymor-
phisms identified by DHPLC were polymorphic in our
population. Of all of the markers that were polymorphic
within the Australian Caucasian population, only
rs7162140 was deemed to have a mior allele frequency of
sufficient magnitude to be examined in our population.
Our results support a role for the rs7162140 T-allele in
risk of cannabis dependence and tobacco dose. We
observed a 26.8% increase in cigarette consumption in
carriers of the T-allele, equating to 20.1 cigarettes per week
(nominal p = 0.01). Therapeutic intervention leading to a
Illustration of the CHRM5 gene locus on chromosome 15q26 Figure 1
Illustration of the CHRM5 gene locus on chromosome 15q26. The two transcripts were defined from the cDNA sequences 
AB084282 (transcript CHRM5. a) and AK095198 (transcript CHRM5. b). Exons are shown as blocks along the genomic 
sequence. The intronic region has been abridged for the purposes of this illustration.
Table 1: Genotype associations between rs7162140 and categorical measures of substance dependence.
Genotype Count
Case Control Model Odds Ratio p-Value
Nicotine Dependence
CC 48 144 Dominant 1.6 (0.90–2.8) 0.11
CT 24 49 Recessive 2.6 (0.65–11.0) 0.17
TT 4 4
Alcohol Dependence
CC 310 50 Dominant 1.3 (0.77–2.0) 0.36
CT 135 28 Recessive 0.95 (0.27–3.3) 0.94
TT 18 3
Cannabis Dependence
CC 40 19 Dominant 2.9 (1.1–7.4) 0.03
CT 9 13 Recessive 1.5 (0.20–11.4) 0.68
TT 2 2
Odds ratio shown with 95% confidence intervals. Analysis based on both dominant (TT|CT > CC) and recessive (TT > CT|CC) inheritance models.BMC Genetics 2007, 8:46 http://www.biomedcentral.com/1471-2156/8/46
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reduction in tobacco consumption at this level would
have considerable public health implications. Carriers of
the T-allele were also found to have an increase in their
risk of cannabis dependence by nearly 3-fold. These data
complement animal models that have shown the M5R is
important in modulating the reward and withdrawal
processes associated with opiate and cocaine use. We did
not observe association between measures of alcohol
dependence or dose. Although our data for tobacco and
cannabis fit a dominant mode of inheritance, we did not
have sufficient power to distinguish between the domi-
nant and heterosis-mode of inheritance for this allele.
Moreover, we would exercise caution in the over interpre-
tation of these data. We have not applied correction for
multiple testing and therefore would support further stud-
ies to confirm or reject these findings.
One strength of this study is the theory-driven approach
to candidate gene selection. From a purely biological per-
spective, the M5R is a strong candidate through its role in
the control of the duration of dopamine release [1,6,7].
Mice lacking a functional M5R have reduced reward and
withdrawal responses following morphine [8] and
cocaine [9] administration. We examined the role of vari-
ation in the CHRM5 gene and dependence on three drugs
of addiction, namely tobacco, alcohol and cannabis. The
dose and dependence variables that we have examined are
derived from phenotypic constructs that are common to
other studies such that cross-study investigation can be
facilitated.
We have attempted to improve the probability of identify-
ing causative genetic loci that influence risk of drugs of
addiction by hypothesis-based candidate polymorphism
choice. Since it is not feasible to screen and study the
entire genomic sequence within the gene locus, we chose
to employ the VAPSE (or Variants Affecting Protein Struc-
ture or Expression) approach [10], whereby analysis is
restricted to gene sequences coding for domains which are
likely to affect protein structure or expression. Under the
VAPSE paradigm, we predict that any functional variation
is measured directly and therefore we exclude confound-
ing associated with linkage disequilibrium. However, as a
precaution analysis was restricted to individuals of Euro-
pean ancestry to lessen genetic and non-genetic con-
founders specific to ethnicity. The rs7162140
polymorphism is transcribed in the CHRM5 message. The
polymorphism is located within the 5' untranslated
region of CHRM5. The specific function of this polymor-
phism on gene expression or function is unknown and
requires further investigation. We acknowledge that our
approach and chosen screening region cannot account for
the influence of long-range regulatory elements or that of
epigenetic modifications that alter the function of the
CHRM5 gene. However, consistent with our study design,
a recent report indicates that polymorphisms that alter
gene expression are strongly biased towards the core and
proximal promoter elements [11].
Studies on rats deficient in M5R have shown that mid-
brain M5R mediate the duration of forebrain dopamine
transmission and the maintenance of dopamine-related
reward [6,7]. Moreover, mice lacking a functional M5R
were shown to have reduced reward and withdrawal
responses following morphine [8] and cocaine [9] admin-
istration. M5R -/- mice show reduced self administration
of cocaine compared to M5R +/+ controls [9]. Our data
show that polymorphisms within the CHRM5 gene locus
increase tobacco use, suggesting increased reward and
withdrawal following substance use in the subset contain-
ing the rs7162140 T-allele. Combined with data from ani-
mal models we would hypothesise that the rs7162140 T-
allele, or an allele in linkage disequilibrium enhances the
functional capacity of the M5R compared to the C-allele.
Table 2: Genotype association between rs7162140 and quantitative measures of substance dependence.
n Mean SD Model p-Value (two-tailed)
Tobacco Dose
CC 192 74.9 55.1 Dominant 0.01
CT 73 97.0 70.9 Recessive 0.84
TT 8 76.6 35.8
CT|TT 81 95.0 68.4
Alcohol Dose
CC 354 20.1 21.8 Dominant 0.81
CT 161 21.1 21.1 Recessive 0.41
TT 21 16.4 16.2
CT|TT 182 20.6 20.7
Alcohol dose described as units (10 g) per week. Tobacco dose described as cigarettes smoked per week. Analysis based on both dominant (TT|CT 
> CC) and recessive (TT > CT|CC) inheritance models using the Student's t-test (two-tailed) to measure equality of means.BMC Genetics 2007, 8:46 http://www.biomedcentral.com/1471-2156/8/46
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Daily tobacco dose is associated with nicotine depend-
ence in our sample (Student's T-test; mean cigarettes per
week of current smokers, subsyndromal nicotine depend-
ent = 55.7, nicotine dependent = 129.9; p < 0.0001). We
observe a statistically non-significant increase in nicotine
dependence in this sample (Dominant model OR = 1.6
(95%CI 0.9–2.8). One reason for the lack of association
for the categorical dependence traits may be the limitation
of sample size (nicotine dependence n = 273, cannabis
dependence n = 85).
Our overall hypotheis was that CHRM5 would influence
tobacco, alcohol and cannabis dependence. Our data does
not support the role of CHRM5 as a generalised risk factor
for drug dependence. Instead our data suggest specific
effects for tobacco and cannabis but not alcohol. One
explanation for this phenomenon can be drawn from the
proposed action of the nicotine, alcohol and cannabis
within the mesolimbic system. In the mesolimbic system,
both nicotine (the active-compound in tobacco) and
delta9-tetrahyrocannabinol (delta9-THC) (the active-
compound in cannabis) act predominantly through
receptor-mediated pathways. Specifically, nicotine oper-
ates through activation of nicotinic acetylcholine receptor
(nAChR) complexes; delta9-THC operates through activa-
tion of the neural cannabinoid receptor, CB1R. As with
M5R, the nAChR are co-expressed on dopamine neurones
of the SNc and VTA [12]. The CB1R are present in the VTA
and are co-expressed with dopamine neurones of the
nucleus accumbens [13]. Interestingly, CB1R knockout
mice show similar reduced reward and withdrawal to
M5R knockout mice [14]. Clearly, the role of nicotine and
delta9-THC in dopaminergic neurotransmission is com-
plex, with receptors also expressed on neurones that are
afferent to the mesolimbic dopamine-containing neu-
rones. However, the co-localisation and direct ligand
action on dopaminergic neurones is common to nicotine
and delta9-THC. Conversely, although ethanol adminis-
tration stimulates neurones within the VTA, ethanol is
thought to elicit its effect through a non-ligand interaction
with receptor proteins on mesolimbic-afferent neurones
containing GABAA  (gamma-aminobutyric acid type-A)
and NMDA (N-methyl-D-aspartate) receptors [4]. This
mode of action, specifically the predominant role of etha-
Table 3: List of oligonucleotide primers, PCR conditions and oven temperatures used, for amplification and DHPLC mutational 
analysis of the human muscarinic acetylcholine receptor M5 gene.
PCR Conditions
Fragment Name Primer Sequence 
Forward
Primer Sequence 
Reverse
Tm (°C) Mg++ (mM) Amplicon Size (bp) Tm (DHPLC)
5'Exon 1. b-1 catctgctcctttctttctt
cc
tgagaaatcctggttgttc
ct
59 2.5 469 56,58
Exon 1. b-1 ttctgaaatacgaacaag
caga
gcacgagcagatttaattt
ca
58 2 449 51,55,56
5'Exon 2. a-1 gggtcttgctatgtcatcc
ag
ccttatgggaccactgttg
taaa
60 2 387 60,55.5
5'Exon 2. a-2 tgcaccacataccattttg
g
ccggacacaatatcactg
tctt
60 2 437 51,53,57
Exon 2. a-1 cattttgctgaccctaaag
acc
tggacgcactacctttaa
aaac
60 2 299 58,59,60
Exon 3. b-1 taacagcccctttgtgaa
cg
cctgtgggagaaatgtggt
t
60 2.5 418 57,60,61
Exon 4. a|b-1 acaagaaaatcatgctgg
tgtg
aggttcatggagaagattc
caa
60 2 383 58,60
Exon 4. a|b-2 gccagctcaagacagtta
acaa
agagaaactggatctggc
actc
60 2 390 60,61
Exon 4. a|b-3 ttgggaagcggacagttc tagctgctacaggtggtga
gc
62 1.5 400 60,61,62
Exon 4. a|b-4 caattgggccaaagctga
g
Ctttcgttgaaggttcctt
gg
60 2 374 59,60
Exon 4. a|b-5 atggctgtcacaaggtga
aaat
tgccagtacaacttctctt
cca
60 2 394 58,59,60
Exon 4. a|b-6 ctttaagatgctgcttctc
tgc
tcattgttacccagtgtgc
ttc
60 2 384 57,59
Exon 4. a|b-7 gggagtttgccaatgaagt
aaa
caagaccttcactcagat
gtgg
60 1.5 375 55,57,59
Tm, annealing temperature for PCR amplification; Mg++, magnesium concentration for PCR amplification; bp, base pairs; Tm DHPLC, column 
temperature (°C) for denaturing high performance liquid chromatography (DHPLC) analysis.BMC Genetics 2007, 8:46 http://www.biomedcentral.com/1471-2156/8/46
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nol in neurones afferent to the mesolimbic dopamine/
M5R-containing neurones may in part explain the lack of
association seen between CHRM5 and alcohol depend-
ence and dose in this study.
In addition to the role in substance dependence, CHRM5
may also be important in other psychiatric disorders
where dysregulation of dopaminergic neurotransmission
has been implicated. A recent study examined the role of
CHRM5 in schizophrenia. The marker rs623941, located
within intron 3, 2.3 kb 5' of exon 4, was not associated
with schizophrenia [15]. A second marker in the alpha7-
cholinergic nicotinic acetylcholine receptor (CHRNA7)
locus was not linked with schizophrenia. When examined
together the authors reported linkage with schizophrenia.
However, the CHRM5-CHRNA7  two-marker haplotype
extends over 3 Mb of genomic DNA and is unlikely to
describe an ancestral chromosome block. Consequently,
the linkage of the CHRM5-CHRNA7 haplotype with schiz-
ophrenia is unlikely to represent evidence due to linkage
disequilibrium with functional markers in either gene.
Conclusion
Animal models clearly show a role of the M5R in modu-
lating dependence to drugs of addiction. Interestingly,
herbal extracts containing known muscarinic receptor
antagonists – such as scopolamine – have already been
documented as useful therapies for opium addiction [16].
We show that CHRM5 the gene that codes for the M5R
contains variations that influence the risk of substance
dependence and dose in a population of young adults.
Our data is the first to show an association between this
gene and substance behaviours in humans and should be
investigated further as potential pharmacogenetic target
in the treatment in addiction.
Methods
Study participants
Screening population for polymorphism detection and validation
A screening sample for polymorphism detection and vali-
dation was drawn from a population of adolescents in the
state of Victoria, Australia (Health In Transition Survey,
1994–2000) [17]. The screening sample was restricted to
European Caucasian ancestry to avoid confounding by
ethnicity. Fifteen individuals from the screening popula-
tion were used to identify common polymorphisms in
CHRM5.
Cohort population for association analysis
Association between substance use behaviour and
CHRM5 was investigated using longitudinal data from a
population-based cohort of an initial potential sample of
2032 adolescents in Victoria, Australia. Participants were
followed from the age of 14 to 24 years (Victorian Adoles-
cent Health Cohort (VAHCS), 1992-present). The sample
was defined in a two-stage procedure. Firstly, 45 schools
were selected from a stratified frame of Government,
Independent, and Catholic schools with a probability
proportional to the number of Year 9 (mid-secondary
school) students in each school stratum in the state. A sin-
gle intact class was selected at random from each of these
schools to constitute the wave one sample. At the second
Table 4: List of oligonucleotide primers, PCR conditions and restriction enzymes used to discriminate genotypes and allele frequency 
in Victorian European Caucasian population of putatively functional human muscarinic acetylcholine receptor M5 gene 
polymorphisms.
PCR Conditions
SNP id Primer Sequence 
Forward
Primer Sequence 
Reverse
Tm (°C) Mg++ (mM) Restriction 
Enzyme
Minor Allele 
Frequency
rs661968 gaagcattcaatgaatctt
caataagttct
atgcggtagatgaagact
cc
55 2.5 MseI C = 0.03
rs7162140 cattttgctgaccctaaag
acc
tggacgcactacctttaa
aaac
60 2 TaqI T = 0.19
-257A>T taacagcccctttgtgaa
cg
cctgtgggagaaatgtggt
t
60 2.5 NlaIII A = 0.03
rs2702309 ggcaaacaacttgaccca
cagaaaacga
cctgtgggagaaatgtggt
t
60 2 MboII A = 0.00
rs2702304 gaaaaaagtgactatgac
accccaaactag
tgattttcaccttgtgaca
gc
59 2 SpeI T = 0.00
rs2576302 atggctgtcacaaggtga
aaat
tgccagtacaacttctctt
cca
60 to 54 TD 2 DdeI T = 0.00
rs2705353 atggctgtcacaaggtga
aaat
tgccagtacaacttctctt
cca
60 to 54 TD 2 AlwNI A = 0.00
Tm, annealing temperature for PCR amplification; TD, touchdown cycling conditions; Mg++, magnesium concentration for PCR amplification; 
touchdown, refers to -0.5°C change in Tm per amplification cycle.BMC Genetics 2007, 8:46 http://www.biomedcentral.com/1471-2156/8/46
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wave of data collection, six months later, a second intact
class from each participating school was selected at ran-
dom. A total of 44 schools were included in the study (24
Government, 11 Catholic and 9 Independent private
schools). The first six waves of data collection were under-
taken at 6-monthly intervals between 1992 and 1996. The
last two survey waves were in 1998 and 2002. The survey
was designed to allow DSM-IV and ICD-10 diagnoses of
common mental health and behavioural problems.
Among a range of psychosocial variables, the VAHCS has
repeated measures on tobacco use. DNA was collected
from all consenting participants. The VAHCS has main-
tained high participant retention with an average response
rate of 80% (min 75%, max 86%). 960 participants of the
1517 participants who were interviewed in wave-8 pro-
vided DNA for genetic analysis (DNA response rate =
63.3%). For each wave of data collection, ethics approval
has been provided by the Royal Children's Hospital Ethics
in Human Research Committee, Melbourne, Australia.
All genetic analyses were restricted to individuals of Euro-
pean descent defined by country of birth across three gen-
erations (participants, parents, grandparents). "European
ancestry" included individuals from non-European
nations populated by predominantly European Caucasian
migration (i.e. Australia, New Zealand, Canada and the
United States of America). There was no significant bias in
wave-8 participants who consented to provide DNA for
this study compared those who did not consent. Genotyp-
ing was performed and analysed on a European ancestry
cohort of 815 participants.
Phenotype definition
Substance use was described in current users within the
VAHCS participants using data from the most recent sur-
vey (wave 8). Tobacco dose, nicotine dependence, alcohol
dose and alcohol dependence were defined within
VAHCS participants who reported use of the drug within
the week prior to the survey. Five hundred and thirty one
participants reported current tobacco use (n = 273 with
DNA) and 976 reported current alcohol use (n = 536 with
DNA).
Cannabis use was defined as reporting use in the fortnight
prior to the wave 8 survey, with current cannabis use
reported in 176 participants (n = 85 with DNA). Sub-
stance dependence was described using a binary case-
comparison model. Substance dose was measured accord-
ing to quantitative measures.
Nicotine dependence was measured using the Fagerstrom
Test for Nicotine Dependence (FTND) [18] in current
smokers. Nicotine dependence was classified as reporting
a FTND score equal to or greater than 4. Subsyndromal
nicotine dependence was defined as scoring between one
and three on the FTND; 147 participants met criteria for
nicotine dependence (with DNA = 76) compared to 384
for subsyndromal-nicotine dependent controls (with
DNA = 197). Alcohol and cannabis dependence was
defined using the Composite International Diagnostic
Interview 2.1, 12-month version (CIDI) [19]; 163 partici-
pants met criteria for alcohol dependence (with DNA =
81) compared to 813 non-alcohol dependent controls
(with DNA = 463); 75 participants met criteria for canna-
bis dependence (with DNA = 34) compared to 101 non-
cannabis dependent controls (with DNA = 51). CIDI ena-
bles a DSM-IV diagnosis of dependence, which required
evidence that within the previous twelve months three of
the following seven criteria must be met; (1) tolerance to
the substance; (2) symptom of withdrawal upon cessation
or reduced use; (3) substance used in larger amounts or
for periods longer than intended; (4) persistent desire or
inability to reduce or cease use; (5) a disproportionate
amount of time in activities related to obtaining, using
and recovering from use; (6) a significant reduction in
social, recreational and occupational activities owing to
substance use; and (7) continued use despite knowledge
of the physical and psychological problems induced by
the substance [20].
Quantitative measures of tobacco and alcohol dose were
obtained using a substance use diary for the week prior to
the wave 8 interviews (tobacco dose: cigarettes per week
(n = 531 (273 with DNA)); alcohol dose: units (10 g) of
alcohol per week (n = 962 (536 with DNA)). The variabil-
ity in cannabis preparation, quality and administration
precluded the administration of a quantitative variable of
cannabis dose in our cohort.
In Silico analysis of the CHRM5 locus
The gene structure of CHRM5  was described through
AceView, based on Build 35.1 data [21]. Specifically, gene
structure was reconstructed by co-alignment of publicly
available mRNA and expressed sequences. In silico
sequence variation detection was performed using the
dbSNP repository [22].
Conditions for denaturing high-performance liquid 
chromatography (DHPLC)
Thirteen amplicons, covering 4588 bp of the CHRM5
locus were used, which covered the transcribed and splice
junctions of exons 1 to 4. In addition, we screened 500 bp
5' to the transcription start sites of exon 1 and 700 bp 5'
to exon 2, to examine the putative promoter region.
DHPLC was performed on the Helix Automated DNA
Analysis and Mutation Detection System (Varian Inc.)
using the Helix DNA Column (Part No, CP28353; Varian,
Inc) according to the manufacturers guidelines. Column
temperature guidelines for DHPLC analysis were obtained
using the online Stanford DNAMelt programme [23]. Oli-BMC Genetics 2007, 8:46 http://www.biomedcentral.com/1471-2156/8/46
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gonucleotide sequences, amplification conditions and
oven temperatures used for screening are listed in Table 3.
Putative heterozygous samples and a representative
homozygous control were sequenced in both forward and
reverse strands in order to characterise the polymorphism.
Sequence chromatograms were reviewed manually to
identify polymorphisms.
Genotyping of CHRM5 polymorphisms
Prior to association analysis allele frequencies were deter-
mined in the screening population. An arbitrary mini-
mum minor allele frequency of 5% was used as a
threshold for further analysis. All SNP genotyping was
performed by restriction fragment length analysis. Experi-
mental details including oligonucleotide sequences,
amplification conditions and the restriction enzyme used
for analysis are detailed in Table 4.
Statistical analysis
All traits were examined against genotype data under a
dominant (AA or Aa > aa) and recessive (AA > Aa or aa)
model. Categorical data, including nicotine dependence,
alcohol dependence and cannabis dependence, were ana-
lysed using logistic regression. Quantitative traits includ-
ing alcohol dose (units per week) and tobacco dose
(cigarettes per week) were analysed using two-tailed Stu-
dent's t-test to assess the equality of means across inherit-
ance models.
No adjustment was made for multiple testing [14]
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